Table 1.
Univariate and multivariate analysis of risk factors in relation to OS in CRLM.
| Parameter | N | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| HR(95%CI) | p value | HR(95%CI) | P value | |||
| Sex | Female | 30 | 1.099(0.681-1.771) | 0.700 | ||
| Male | 55 | Ref | ||||
| Age(years) | <60 | 45 | Ref | |||
| ≥60 | 40 | 1.347(0.856-2.120) | 0.198 | |||
| Viral hepatitis | positive | 9 | 1.390(0.664-2.908) | 0.383 | ||
| negative | 76 | Ref | ||||
| Timing of liver metastases | Synchronous liver metastases | 53 | Ref | |||
| Metachronous liver metastases | 32 | 0.674(0.419-1.084) | 0.104 | |||
| Primary lesion site | Left hemi-colon | 63 | Ref | |||
| Right hemi-colon | 22 | 1.584(0.961-2.610) | 0.071 | |||
| Size of primary tumor (mm) | <50 | 53 | Ref | |||
| ≥50 | 32 | 1.564(0.987-2.480) | 0.057 | |||
| Size of metastases (mm) | <30 | 48 | Ref | |||
| ≥30 | 37 | 1.670(1.057-2.636) | *0.028 | 1.475(0.865-2.514) | 0.153 | |
| number of liver metastases | 1 | 52 | ||||
| >1 | 33 | 2.326(1.426-3.792) | *0.001 | 1.522(0.911-2.542) | 0.109 | |
| sCEA(ng/ml) | <5 | 18 | Ref | |||
| ≥5 | 67 | 1.456(0.813-2.607) | 0.206 | |||
| sCA-199(ng/ml) | <35 | 51 | Ref | |||
| ≥35 | 34 | 2.472(1,537-3.975) | *< 0.001 | 2.275(1.302-3.975) | *0.004 | |
| N stage | N0 | 31 | Ref | |||
| N1-2 | 54 | 3.007(1.722-5.250) | *< 0.001 | 2.232(1.239-4.020) | *0.008 | |
| T stage | T1-2 | 7 | Ref | |||
| T3-4 | 78 | 1.637(0.594-4.508) | 0.559 | |||
| Degree of differentiation | High or Moderately differentiation | 77 | Ref | |||
| Poorly differentiation | 8 | 1.464(0.667-3.214) | 0.342 | |||
| Tumor types | Uplift type | 7 | 1.331(0.862-2.056) | 0.197 | ||
| Ulcer type | 74 | |||||
| invasive | 4 | Ref | ||||
| Lymphovascular invasion | Absent | 40 | Ref | |||
| Present | 45 | 2.355(1.443-3.842) | *0.001 | 1.793(1.030-3.121) | *0.039 | |
| Nerve invasion | Negative | 36 | Ref | |||
| Positive | 49 | 1.558(0.964-2.517) | 0.070 | |||
| Ki67(%) | <70% | 51 | Ref | |||
| ≥70% | 34 | 3.200(1.738-5.890) | *< 0.001 | 2.700(1.388-5.253) | *0.003 | |
| MMR | dMMR | 16 | Ref | |||
| pMMR | 69 | 4.899(2.378-10.092) | *< 0.001 | 2.213(1.181-4.993) | *0.046 | |
| Chemotherapy regimen | 5-Fu-based | 32 | Ref | |||
| Capecitabine -based | 53 | 1.560(0.960-2.535) | 0.073 | |||
* Statistically significant correlation. sCEA, preoperative serum CEA; sAFP, preoperative serum CA199; pMMR, Mismatch Repair Proficiency; dMMR, Mismatch Repair Deficiency; Ref, reference variables. Bold values means statistical differences.